Evidence map›Paper›PMID 36229813›Full record

ArticleBMC complementary medicine and therapies2022

Reproductive and endocrine effects of artemisinin, piperaquine, and artemisinin-piperaquine combination in rats.

Xiaobo Li, Yueming Yuan, Yingyi Chen, Li Ru, Zheng Yuan, Zhiyong Xu, Qin Xu, Jianping Song, Guoming Li, Changsheng Deng

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaobo Li *Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yueming Yuan *Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yingyi ChenArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Li RuArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zheng YuanSci-tech Industrial Park, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhiyong XuSci-tech Industrial Park, Guangzhou University of Chinese Medicine, Guangzhou, China.
Qin XuArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jianping SongArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guoming LiArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China. liguoming202218@163.com.
Changsheng DengArtemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China. dcs@gzucm.edu.cn.
Guangzhou University of Chinese Medicine · CN

Funding

Natural Science Foundation of China 81873218Science and Technology Project of Guangdong Province 2021A0505030060
6 · The paper itself

Abstract

backgroundThe WHO recommends artemisinin-based combination regimens for uncomplicated Plasmodium falciparum malaria. One such combination is artemisinin-piperaquine tablets (ATQ). ATQ has outstanding advantages in anti-malarial, such as good efficacy, fewer side effects, easy promotion and application in deprived regions. However, the data about the reproductive and endocrine toxicity of ATQ remains insufficient. Thus, we assessed the potential effects of ATQ and its individual components artemisinin (ART) and piperaquine (PQ) on the reproductive and endocrine systems in Wistar rats.

methodsThe unfertilized female rats were intragastric administrated with ATQ (20, 40, and 80 mg/kg), PQ (15, 30, and 60 mg/kg), ART (2.5, 5, and 10 mg/kg), or water (control) for 14 days, respectively. The estrous cycle and serum levels of estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), prostaglandin (PG), and adrenocorticotropic hormone (ACTH) were determined. The weights of the kidney, adrenal gland, uterus, and ovaries were measured. The histopathological examinations of the adrenal gland, ovary, uterus, and mammary gland were performed.

resultsCompared with the control group, there were no significant differences in the examined items of female rats in the ART groups, including general observation, estrous cycle, hormonal level, organ weight, and histopathological examination. The estrous cycle of female rats was disrupted within 4-7 days after ATQ or PQ administration, and then in a persistent dioestrus phase. At the end of administration, ATQ and PQ at three doses induced decreased PG, increased ACTH, increased adrenal weight and size, and pathological lesions in the adrenal gland and ovary, including vasodilation and hyperemia in the adrenal cortex and medulla as well as hyperplasia and vacuolar degeneration, ovarian corpus luteum surface hyperemia, numerous but small corpus luteum, and disordered follicle development. But the serum levels of E2, FSH, LH, and PRL did not change obviously. These adverse effects in ATQ or PQ treated rats could not completely disappear after 21 days of recovery.

conclusionBased on the results of this study, ART had no obvious reproductive and endocrine effects on female rats, while ATQ and PQ caused adrenal hyperplasia, increased ACTH, decreased PG, blocked estrus, corpus luteum surface hyperemia, and disrupted follicle development in female rats. These events suggest that ATQ and PQ may interfere with the female reproductive and endocrine systems, potentially reducing fertility.

Indexed as

AntimalarialsArtemisininsHyperemiaAdrenocorticotropic HormoneAnimalsEstradiolFemaleFollicle Stimulating HormoneHyperplasiaLuteinizing HormonePiperazinesProlactinProstaglandinsQuinolinesRatsRats, WistarAdrenocorticotropic HormoneAntimalarialsartemisininArtemisininsEstradiolFollicle Stimulating HormoneLuteinizing HormonepiperaquinePiperazinesProlactinProstaglandinsQuinolinesArtemisininEndocrinePiperaquineRatsReproduction

Identifiers

PMID36229813
PMCPMC9560020
OpenAlexW4304893148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.